Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
- 16 April 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 113 (16), 3885-3886
- https://doi.org/10.1182/blood-2009-01-196329
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximabRheumatology, 2008
- Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuriaNature Biotechnology, 2007
- Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapyHematology, 2007
- Cold antibody autoimmune hemolytic anemiasBlood Reviews, 2007
- Cold agglutinin disease revealing mediastinal seminomaQJM: An International Journal of Medicine, 2007
- Faculty Opinions recommendation of Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.Published by H1 Connect ,2006
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2006
- The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma HemoglobinJAMA, 2005
- Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2004
- Inhibition of complement activity by humanized anti-C5 antibody and single-chain FvMolecular Immunology, 1996